New Game-Changing Obesity Drug Dramatically Reduces Risk of Type 2 Diabetes
According to new research, the revolutionary new obesity drug semaglutide cuts the risk of type 2 diabetes by more than 50%.The risk of type 2 diabetes is reduced by more than half by weekly injections of the new obesity drug Wegovy (semaglutide). This is according to new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden (September 19-23).Semaglutide was recently approved in the US by the Food and Drug Administration as an obesity treatment and…